{"title":"基于布利纳单抗的复发/难治性b细胞急性淋巴母细胞白血病抢救：来自印度单一中心的“真实世界”经验","authors":"Vaibhav Chadha, Garima Nirmal, Goutomi Chatterjee, Subhasish Paul, Gurpreet Singh, Nikhil Gupta, Gaurav Kharya","doi":"10.1016/j.phoj.2025.03.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Blinatumomab is effective in achieving disease remission in children with CD-19 positive relapsed/refractory (R/R) B-lineage acute lymphoblastic leukemia (B-ALL).</div></div><div><h3>Case series</h3><div>Blinatumomab was administered to nine patients with R/R B-ALL, of which 8 (88 %) were not in remission post-salvage chemotherapy. Seven of eight (87.5 %) patients attained morphological remission, and 5/8 (62.5 %) had measurable residual disease response following the first cycle. Three received a second cycle; 2 were non-responsive, and 1 had progressive disease during therapy. Cytokine release syndrome Grade 3 was seen in 2/9 (22 %) patients. Seven (78 %) underwent hematopoietic stem cell transplant. At a median follow-up of 650 days, the overall survival and progression-free survival of the cohort was 55.6 % (±16.6).</div></div><div><h3>Conclusion</h3><div>Our case series emphasizes the feasibility and ease of administration of blinatumomab with minimal toxicity, and efficacy similar to international reports in a resource-limited setting.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"10 2","pages":"Article 100447"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Blinatumomab-based salvage in relapsed/refractory B-cell acute lymphoblastic leukemia: \\\"real world\\\" experience from a single-centre in India\",\"authors\":\"Vaibhav Chadha, Garima Nirmal, Goutomi Chatterjee, Subhasish Paul, Gurpreet Singh, Nikhil Gupta, Gaurav Kharya\",\"doi\":\"10.1016/j.phoj.2025.03.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Blinatumomab is effective in achieving disease remission in children with CD-19 positive relapsed/refractory (R/R) B-lineage acute lymphoblastic leukemia (B-ALL).</div></div><div><h3>Case series</h3><div>Blinatumomab was administered to nine patients with R/R B-ALL, of which 8 (88 %) were not in remission post-salvage chemotherapy. Seven of eight (87.5 %) patients attained morphological remission, and 5/8 (62.5 %) had measurable residual disease response following the first cycle. Three received a second cycle; 2 were non-responsive, and 1 had progressive disease during therapy. Cytokine release syndrome Grade 3 was seen in 2/9 (22 %) patients. Seven (78 %) underwent hematopoietic stem cell transplant. At a median follow-up of 650 days, the overall survival and progression-free survival of the cohort was 55.6 % (±16.6).</div></div><div><h3>Conclusion</h3><div>Our case series emphasizes the feasibility and ease of administration of blinatumomab with minimal toxicity, and efficacy similar to international reports in a resource-limited setting.</div></div>\",\"PeriodicalId\":101004,\"journal\":{\"name\":\"Pediatric Hematology Oncology Journal\",\"volume\":\"10 2\",\"pages\":\"Article 100447\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Hematology Oncology Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468124525000087\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology Oncology Journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468124525000087","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Blinatumomab-based salvage in relapsed/refractory B-cell acute lymphoblastic leukemia: "real world" experience from a single-centre in India
Background
Blinatumomab is effective in achieving disease remission in children with CD-19 positive relapsed/refractory (R/R) B-lineage acute lymphoblastic leukemia (B-ALL).
Case series
Blinatumomab was administered to nine patients with R/R B-ALL, of which 8 (88 %) were not in remission post-salvage chemotherapy. Seven of eight (87.5 %) patients attained morphological remission, and 5/8 (62.5 %) had measurable residual disease response following the first cycle. Three received a second cycle; 2 were non-responsive, and 1 had progressive disease during therapy. Cytokine release syndrome Grade 3 was seen in 2/9 (22 %) patients. Seven (78 %) underwent hematopoietic stem cell transplant. At a median follow-up of 650 days, the overall survival and progression-free survival of the cohort was 55.6 % (±16.6).
Conclusion
Our case series emphasizes the feasibility and ease of administration of blinatumomab with minimal toxicity, and efficacy similar to international reports in a resource-limited setting.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
